Histiocytic Disorders: Recent Insights into Pathophysiology and Practical Guidelines

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 1, 2010, Pages S82-S89

  Filipovich, Alexandra ^a   McClain, Kenneth ^b   Grom, Alexei ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b TEXAS CHILDREN S CANCER CENTER   (United States)

Author keywords

Hemophagocytic Lymphohistiocytosis (HLH); Langerhans Cell Histiocytosis (LCH); Macrophage Activation Syndrome (MAS)

Indexed keywords

CLADRIBINE; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; IMMUNOGLOBULIN; MERCAPTOPURINE; METHOTREXATE; PREDNISONE; RITUXIMAB; STEROID; THYMOCYTE ANTIBODY; VINBLASTINE SULFATE;

ARTICLE; BONE MARROW BIOPSY; GENETIC DISORDER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHAGOCYTIC SYNDROME; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; LABORATORY DIAGNOSIS; LANGERHANS CELL HISTIOCYTOSIS; MACROPHAGE ACTIVATION SYNDROME; PATHOGENESIS; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; GENETICS; HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS; HISTIOCYTOSIS; HISTIOCYTOSIS X; METABOLISM; REVIEW;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTIOCYTOSIS; HISTIOCYTOSIS, LANGERHANS-CELL; HUMANS; LYMPHOHISTIOCYTOSIS, HEMOPHAGOCYTIC; MACROPHAGE ACTIVATION SYNDROME;

EID: 77953040665     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.014     Document Type: Article

References (39)

1. Braier, J., Latella, A., Balancini, B., et al. Outcome in children with pulmonary Langerhans cell Histiocytosis. Pediatric Blood Cancer 43 (2004), 765–769.
2. Bernard, F., Thomas, C., Bertrand, Y., et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 41 (2005), 2682–2689.
3. Dunger, D.B., Broadbent, V., Yeoman, E., et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med 321 (1989), 1157–1162.
4. Grois, N., Pötschger, U., Prosch, H., et al. Risk factors for diabetes insipidus in Langerhans cell histiocytosis. Pediatric Blood Cancer, 46, 2006, 228.
5. Wnorowski, M., Prosch, H., Prayer, D., et al. Pattern and course of neurodegeneration in Langerhans cell histiocytosis. J Pediatr 153 (2008), 127–732.
6. Allen, C.E., Flores, R., Rauch, R., Dauser, R., et al. Neurodegenerative central nervous system langerhans cell histiocytosis and coincident hydrocephalus: efficacy of vincrisitne cytosine arabinoside treatment. Pediatric Blood Cancer, 2009.
7. Jordan, M., McClain, K.L., Yan, X., et al. Langerhans cells in langerhans cell histiocytosis express CD 52 (Campath). Pediatr Blood Cancer 44 (2005), 251–255.
8. Kesik, V., Citak, C., Kismet, E., et al. Hematopoietic stem cell transplantation in Langerhans cell histiocytosis: case report and review of the literature. Pediatr Transplant 13 (2008), 371–374.
9. Kudo, K., Ohga, S., Morimoto, A., et al. Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant, 2009 [Epub ahead of print].
10. Steiner, M., Matthes-Martin, S., Attarbaschi, A., et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 36 (2005), 215–225.
11. Snow, A.L., Marsh, R.A., Krummey, S.M., et al. Restimulation-induced apoptosis of T cells is impaired in patients with X-linked lymphoproliferative disease caused by SAP deficiency. J Clin Invest 119 (2009), 2976–2989.
12. Stepp, S.E., Dufourcq-Lagelouse, R., Le Deist, F., et al. Perforin gene defects in familial hemophagocytic lymphohistiocytosis. Science 286 (1999), 1957–1959.
13. Feldmann, J., Callebaut, I., Raposo, G., et al. Munc13-4 is essential for cytolytic granules fusion and is mutated in a form of familial hemophagocytic lymphohistiocytosis (FHL3). Cell 115 (2003), 461–473.
14. zur Stadt, U., Schmidt, S., Kasper, B., et al. Linkage of familial hemophagocytic lymphohistiocytosis (FHL) type-4 to chromosome 6q24 and identification of mutations in syntaxin 11. Hum Mol Genet 14 (2005), 827–834.
15. zur Stadt, U., Rohr, J., Seifert, W., et al. Familial hemophagocytic lymphohistiocytosis type 5 (FHL-5) is caused by mutations in Munc18-2 and impaired binding to syntaxin 11. Am J Hum Genet 85 (2009), 482–492.
16. Rigaud, S., Fondaneche, M.C., Lambert, N., et al. XIAP deficiency in humans causes an X-linked lymphoproliferative syndrome. Nature 444 (2006), 110–114.
17. Henter, J.I., Horne, A., Arico, M., et al. HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatric Blood Cancer 48 (2007), 124–131.
18. Allen, C.E., Yu, X., Kozinetz, C.A., et al. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer 51 (2007), 710–711.
19. Komp, D.M., McNamara, J., Buckley, P., et al. Elevated soluble interleukin-2 eceptor in childhood hemophagocytic histiocytic syndromes. Blood 73 (1989), 2128–2132.
20. Horne, A., Janka, G., Maarten Egeler, R., et al. Haematopoietic stem cell transplantation in haemophagocytic lymphohistiocytosis. Br J Haematol 129 (2005), 622–630.
21. Cesaro, S., Locatelli, F., Lanino, E., et al. Hematopoietic stem cell transplantation for hemophagocytic lymphohistiocytosis: a retrospective analysis of data from the Italian Association of Pediatric Hematology Oncology (AIEOP). Haematologica 93 (2008), 1694–1701.
22. Sreedharan, A., Bowyer, S., Wallace, C.A., et al. Macrophage activation syndrome and other systemic inflammatory conditions after BMT. Bone Marrow Transplant 37 (2006), 629–634.
23. Ohga, S., Kudo, K., Ishii, E., et al. Hematopoietic stem cell transplantation for familial hemophagocytic lymphohistiocytosis and Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Japan. Pediatr Blood Cancer, 2009 [Epub ahead of print].
24. Cooper, N., Rao, K., Gilmour, K., et al. Stem cell transplantation with reduced-intensity conditioning for hemophagocytic lymphohistiocytosis. Blood 107 (2006), 1233–1236.
25. Silverman, E.D., Miller, J.J., Bernstein, B., et al. Consumption coagulopathy associated with systemic juvenile rheumatoid arthritis. J Pediatr 103 (1983), 872–876.
26. Sawhney, S., Woo, P., Murray, K.J., Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child 85 (2001), 421–426.
27. Stephan, J.L., Kone-Paut, I., Galambrun, C., et al. Reactive Haemophagocytic syndrome in children with inflammatory disorders. A retrospective study of 24 patients. Rheumatology (Oxford) 40 (2001), 1285–1292.
28. Grom, A.A., NK dysfunction: a common pathway in systemic onset juvenile rheumatoid arthritis, macrophage activation syndrome, and hemophagocytic lymphohistiocytosis. Arthritis Rheum 50 (2004), 689–698.
29. Grom, A.A., Villanueva, J., Lee, S., et al. Natural killer cell dysfunction in patients with systemic-onset juvenile rheumatoid arthritis and macrophage activation syndrome. J Peds 142 (2003), 292–296.
30. Villanueva, J., Lee, S., Giannini, E.H., et al. Natural killer cell dysfunction is a distinguishing feature of systemic onset juvenile rheumatoid arthritis and macrophage activation syndrome. Arthritis Res Ther 7 (2005), R30–R37.
31. Vastert, M., Wulffraat, N., Mutations in the perforin gene can be linked to MAS in sJIA. PRES/EULAR, 2009 abstract.
32. Hazen, M.M., Woodward, A.L., Hofman, I., et al. Mutations of the hemophagocytosis-associated gene UNC13D in a patient with systemic juvenile idiopathic arthritis. Arthritis Rheum 58 (2008), 567–570.
33. Zhang, K., Biroscak, J., Glass, D.N., et al. Macrophage activation syndrome in systemic juvenile idiopathic arthritis is associated with MUNC13D gene polymorphisms. Arthritis Rheum 58 (2008), 2892–2896.
34. Rubin, L.A., The soluble interleukin-2 receptor in rheumatic disease. Arthritis Rheum 33 (1990), 1145–1148.
35. Bleesing, J., Prada, A., Villanueva, J., et al. The diagnostic significance of soluble CD163 and soluble IL2Rα chains in macrophage activation syndrome and untreated new onset systemic juvenile idiopathic arthritis. Arthritis Rheum 56 (2007), 965–971.
36. Mouy, R., Stephan, J.L., Pillet, P., et al. Efficacy of cyclosporine A in the treatment of macrophage activation syndrome in juvenile arthritis: report of five cases. J Pediatr 129 (1996), 750–754.
37. Sandhu, C., Chesney, A., Piliotis, E., et al. Macrophage activation syndrome after etanercept treatment. J Rheumatol 34 (2007), 241–242.
38. Balamuth, N.J., Nichols, K.E., Paessler, M., et al. Use of Rituximab in conjunction with immunosuppressive chemotherapy for EBV-associated hemophagocytic lymphohistiocytosis. J Pediatr Hematol/Oncol 29 (2007), 569–573.
39. Brinkman, D.M., de Kleer, I.M., ten Cate, R., et al. Autologous stem cell transplantation in Children with severe progressive systmic or polyarticular juvenile idiopathic arthritis: long-term follow-up of a prospective clinical trial. Arthritis Rheum 56 (2008), 2410–2421.